Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 11/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796465 | 0.91 | PRMT5 (0.45) | PRMT5WDR77ADK | |
| SCHEMBL5142438 | 0.85 | PRMT5 (0.49) | PRMT5WDR77ADK | |
| SCHEMBL30916861 | 0.82 | PRMT5 (0.45) | PRMT5WDR77ADK | |
| SCHEMBL3929088 | 0.82 | PRMT5 (0.45) | PRMT5WDR77ADK | |
| SCHEMBL4800285 | 0.81 | PRMT5 (0.42) | PRMT5WDR77ADK | |
| SCHEMBL5927313 | 0.81 | ADK (0.32) | ADK | |
| SCHEMBL4016824 | 0.80 | PRMT5 (0.45) | PRMT5WDR77ADK | |
| SCHEMBL6224873 | 0.72 | ADORA2A (0.48) | — | |
| SCHEMBL13302001 | 0.71 | PRMT5 (0.45) | PRMT5WDR77ADK | |
| SCHEMBL4011551 | 0.70 | ALDH1A1 (0.38) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556399-A4 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO INC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20060264389-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | BHAT BALKRISHEN | 2006-11-23 | — | — | US | claimed |
| EP-1556399-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004007512-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20060264389-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | BHAT BALKRISHEN | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264389-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 444/4885WDR77 1752/4885ADK 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.